Monitor court proceedings for approval of bidding procedures and any competing bids. The stock is expected to be delisted and equity holders are likely to receive nothing under the prepackaged plan.
KPTI drugs
KPTI drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 2 $0.1120entry
- T+1 · 14d ago −21.16%α −21.46% · $0.0883
- T+5 · 8d ago −64.29%α −64.36% · $0.0400
- T+10 · todayOpen
- T+20 · in 14d Pending
- T+60 · in 2mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Karyopharm Therapeutics filed for Chapter 11 bankruptcy and entered into a Restructuring Support Agreement with lenders and noteholders for a merger with Ayrmid Ltd. The company states existing equity holders will receive no distribution and expects a complete loss on their investment. The transaction is expected to close in Q1 2027.
Key Facts
- Karyopharm filed voluntary Chapter 11 petitions in the Southern District of Texas on November 2, 2026.
- The company entered into a Restructuring Support Agreement providing for a merger with Ayrmid Ltd.
- Existing common stock and convertible preferred stock holders will receive no payment or distribution.
- The company expects existing equity securities will have no value and holders will experience a complete loss.
- Up to $55 million in debtor-in-possession financing committed by existing secured lenders.
- Transaction expected to close in Q1 2027, subject to court approval and bidding procedures.
- Ayrmid will serve as lead bidder in a court-supervised sale process.
Financial Impact
Existing equity holders to receive zero recovery; $55M DIP financing committed; market cap $20M at analysis time.
Risk Factors
- Equity holders expected to receive no recovery and experience a complete loss.
- Expected delisting from Nasdaq Global Select Market.
- Transaction subject to court approval and potential competing bids could alter outcomes.
- document contains text addressed to automated readers
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-442822 |
| Document: d87273dex991.htm | 0001193125-26-442822 |
| Document: 0001193125-26-442822-index-headers.html | 0001193125-26-442822 |
| Document: 0001193125-26-442822-index.html | 0001193125-26-442822 |
| Document: 0001193125-26-442822.txt | 0001193125-26-442822 |
Track record
30 reports on KPTI
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +97.24% at T+60 after the Aug 13, 2026 report. 12 of 13 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.0102 Now $0.0290 +184.31% settles Feb 12
- Nov 13, 20263d ago NT 10-Q Bearish 7/10 Entry $0.0102 Now $0.0290 −184.31% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $0.0260 Now $0.0290 +11.54% settles Feb 10
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $0.0400 Now $0.0290 −27.50% settles Feb 5
- Nov 5, 202611d ago 8-K Bearish 8/10 Entry $0.0601 Now $0.0290 +51.75% settles Feb 3
- Nov 2, 202614d ago 8-K Bearish 10/10 Entry $0.0883 Now $0.0290 +67.16% settles Feb 1
- Nov 2, 202614d ago 8-K Bearish 7/10 Viewing Entry $0.1120 Now $0.0290 +74.11% settles Jan 29
- Oct 28, 202619d ago SC 13G/A Bearish 5/10 Entry $0.8798 Now $0.0290 +96.70% settles Jan 27
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $0.5175 Now $0.0290 +94.40% settles Jan 21
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $0.3150 Now $0.0290 −90.79% settles Jan 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers